Status:

COMPLETED

Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.

Lead Sponsor:

University of British Columbia

Conditions:

Scoliosis

Eligibility:

All Genders

12-18 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to establish whether rHuEpo is as effective as PAD in increasing red cell mass prior to surgery. Other benefits of the PAD program and preoperative administration of rHuEp...

Detailed Description

Background The pre-operative autologous donation (PAD) program was established at British Columbia's Children's Hospital in 1988 to decrease the need for homologous blood transfusion. It could allevia...

Eligibility Criteria

Inclusion

  • Scoliosis repair

Exclusion

  • \-

Key Trial Info

Start Date :

October 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2007

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00323752

Start Date

October 1 2004

End Date

December 1 2007

Last Update

September 25 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

British Columbia Children's Hospital

Vancouver, British Columbia, Canada

Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children. | DecenTrialz